Moderna, Inc. Common Stock (MRNA) News
Latest headlines that mention MRNA, newest first · each headline opens the original publisher
- Last price
- $197.00
- Day change
- +0.26%
- Next earnings
- 2026-11-05
MRNA headlines
last 30 daysAxsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential.
Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses. The post Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers appeared first on Investor's Business Daily .
With potential profit-taking on the horizon, it could mean Moderna's upside is limited in the short-term. The post After Moderna's 'Outsized Run,' It May Be Time For This Bearish Move appeared first on Investor's Business Daily .
Moderna stock rallied by triple digits when positive news rolled in for its cancer vaccine. But is mRNA ready to return to the limelight? The post Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz appeared first on Investor's Business Daily .
Moderna’s rally has priced in unrealistic expectations for its cancer drug sales.
The company could enter a fresh growth phase.
After nearly quadrupling over the past month, it's time to get out of Moderna stock, a Citi analyst said Wednesday as he downgraded shares. The post After Moderna's Dizzying Rally, It's Time To Sell, Says Analyst appeared first on Investor's Business Daily .
Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase.
Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock.
Moderna's story is changing fast, but the stock is already pricing in a lot. See what the Phase 3 cancer result really proves, what could come next, and where the biggest risk still sits.
Also mentioned with MRNA
30dHeadlines that tag both tickers
MRNA news alerts
Get an alert by email or push when a new headline mentions MRNA.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.